The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Mylan Inc.

  • MYL
  • NASDAQ
  • Consumer Products
  • Latest 52.37
  • Currency US$
  • Change 1.52
  • Percent Change 2.989 %
  • Volume 3,191,064
  • Thu Oct 30, 2014 12:15 PM EDT NASDAQ data delayed 15 minutes.
  • Open 50.49
  • Previous Close 50.85
  • High 52.46
  • Low 50.49
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High03/04 57.52
  • 52-week Low10/31 36.97
  • Beta 0.642
  • Market Cap 19,476.93M
  • EPS 1.46
  • P/E 35.87
  • Forward P/E 12.96
  • PEG 1.08
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $6,993,260,000
  • Earnings $632,730,000
  • Return on Equity 20.57%

Cash Flow

  • Cash Flow --
  • Cash $243,000,000
  • Current Ratio 1.64

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $15,355,000,000
  • Liabilities $12,163,300,000
  • Liabilities-to-Equity Ratio 3.81

Price Ratios

  • Price to Sales 2.79
  • Price to Book 6.10
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Oct 30 $1.14 Feb 26 $0.99
Surprises Aug 7 -1.43% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Oct 31, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

Related Securities
Symbol Type Latest % Chg

Officers

  • Robert J. Coury Executive Chairman and Directo
  • Rodney L. Piatt Vice Chairman and Director
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

1000 MYLAN BOULEVARD
CANONSBURG, PA
15317

Phone: (724)-514-1800
Fax: (724)-5141870


www.mylan.com

Ideas & Discussion

Live Discussion of MYL on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.